Boston firm’s diabetes treatment beats $6B Merck drug in head-to-head trial

A Boston company says that a trial of 535 patients with type 2 diabetes showed its tiny drug pump worked better in a head-to-head comparison with the leading once-a-day pill for the disease, Januvia, which generated more than $6 billion in revenue last year...